Compare Cardinal Health Inc (CAH) vs Expedia Group Inc (EXPE) Price & Performance

Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.

Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.

Expedia Group (EXPE) trades at $314.01, up 1.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $5.76 beating estimates by 10.3% and revenue growth accelerating to 14% year-over-year. Recent earnings show continued B2B momentum and AI-driven efficiency improvements, with the company raising full-year revenue guidance to $16.05-16.22 billion. Valuation metrics remain reasonable with P/E of 20.19 and EV/EBITDA of 10.04, while profitability metrics show impressive ROE of 199.12% and net margin of 12.97%.

Expedia presents a favorable investment case with strong earnings momentum, strategic AI integration, and upward guidance revisions. The stock trades near analyst consensus target of $322.95 with 47% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include travel demand sensitivity to economic conditions and competitive pressures in online travel. The combination of fundamental strength and technical momentum supports a constructive outlook for patient investors.